|
Archive 2003
Top 10 Drugs 2003
Formulary Updates 2003
Posted December 29, 2003
Alberta
DBL Report January 2004
Highlights
Special Authorization: Ezetrol, Spiriva;
Changes to Special Authorization Criteria: Actos;
Products Added: Apo-Carvedilol, PMS-Carvedilol, Co-Simvastatin, Metadol;
Products Not Added: Concerta, Pennsaid
Posted December 23, 2003
New Brunswick
Highlights
New Brunswick Prescription Drug Program Formulary December 2003 and MAC List December 2003: See Formulary for details.
Posted December 22, 2003
Alberta
Alberta Health & Wellness Update effective January 1, 2004
Highlights
Products Added: Accuretic 20/25 Tab, Apo-Ketorolac 0.5% Oph Sol. Apo-Naproxen EC 250,375,500mg Tab, Apo-Verap SR 20,180,240mg SR Tab,
Metadol 1,5,10,25mg Tab, PMS-Pamidronate 30, 90mg/vial Inj, PMS-Pravastatin 10,20,40mg Tab, PMS-Salbutamol 0.4mg/ml OL, Proctol Rectal Oint,
ratio-Ketorolac 0.5% Oph Sol, Rhoxal-Glyburide 2.5, 5mg Tab, Rhoxal-Metoprolol (Type L), 50,100mg Tab, Rhoxalo-Pravastatin 10,20,40mg Tab,
Sodium Aurothiomalate B.P. 10,25,50mg/ml Inj;
Dicontinued Listing: Aristocort 4mg Tab, Atropine 1% Oph Sol, Pentasa 250mg SR Tab, Surmontil 100mg Tab, Voltaren 25mg EC Tab;
Special Authorization: Ezetrol 10mg Tab, Kineret 100mg/syr inj, Spiriva 18mcg Inh Capsule, Gen-Etidronate 200mg Tab,
Changes to SA Criteria: Enbrel 25mg/vial inj, Remicade 100mg/vial inj
Posted December 18, 2003
Nova Scotia
Pharmacare December 2003 Bulletin effective January 1, 2004
Highlights
New Listed Products: Lumigan 0.03% Oph Sol, Risperdal M 0.5, 1, 2mg Tab, Ultrase MS4 Cap, Ultrase MT 12, 20 Cap;
New Exception Status Products: Botox 100u/vial Inj, Estradot Patch 25mcg , Ezetrol 10mg Tab;
Not Insured: Cipro XL 500mg Tab, Elidel 1% Cr, Ketek 400mg Tab, Minirin 0.1mg Tab
Posted December 12, 2003
Québec
15th Edition (October 2003) Modification effective December 10, 2003
Highlights
New Exception Drug: Fuzeon 108 mg
Posted December 5, 2003
British Columbia
Pharmacare Newsletter December 3, 2003
Highlights
Delisted: Apo-Nefazodone, Gen Nefazodone, Lin Nefazodone, Novo Nefazodone, PMS Nefazodone, Serzone;
New Drug Benefits: Apo-Paroxetine 20,30mg Tab, Pms-Paroxetine 20,30mg Tab, Lumigan 0.03% Opth Sol;
Not Recommended for Listing: Pms-Paroxetine Tab 10mg, Apo-Paroxetine Tab 10mg, Xalacom Opth Sol,
Tarka 1/240mg,2/240mg,2/180/,4/240mg Tab, Vagifem 25mcg Vag Tab; New Blood Glucose Test Strip: Ascensia Microfill BC Test Strip;
New LC and/or RDP Products: Ratio-Amcinonide, Apo-Paroxetine, Pms-Paroxetine;
New Limited Coverage Drugs: Bextra 10,20mg Tab, Diovan 80, 160mg, 160/25/mg Tab;
Drugs Under Review: Xatral, Kineret, Botox, Alphagan, Ciproxl, Plavix, DDAVP, Aricept, Enbrel, Ezetrol,
Arixtra, Reminyl, Cytovene, Amaryl, Avonex, Avapro, Keppra, Cozaar, Metadol, Concerta, Zyprexa, Trileptal, Pegasys, Coversyl, Preterax,
Elidel, Actos, Actonel, Risperdal M-Tab, Exelon, Vioxx, Crestor, Avandia, Protopic, Ketek, Androderm, Spiriva, Diaplex;
PPIs - Criteria Change.
Posted December 2, 2003
Alberta
Additions effective December 1, 2003
Highlights
New Drug Products Added: Apo-Paroxetine, Gen-Paroxetine, PMS-Paroxetine, ratio-Paroxetine 20, 30mg Tab;
Change in Benefit Status: Avandia no longer requires Special Authorization
Posted December 1, 2003
Nova Scotia
December 2003 Bulletin
Highlights
New Exception Status Drugs: Rilutek, Urso DS, Zyprexa Zydis, Singular 10mg Tab;
Correction: Methotrexate 10mg/mL Inj is NOT Discontinued;
Updated Criteria: LABA, salmeterol and formoterol;
New Products: Accuretic 20/25Tab, Aromasin 25mg Tab, Coversyl Plus 1.25/4mg Tab, Diovan 80, 160mg Tab, Diovan-HCT 160/25mg tab,
Lovenox HP 150mg/mL Syr Inj, Palladone IR 2,4,8mg Tab, Palladone XL 12,16,24mg Cap, Premplus 0.625/5mg Tb, Quinine-Odan 300mg Tab,
ratio-Methylphenidate 5mg Tab,Scopolamine 0.4, 0.6mg/mL Inj, Sensorcaine 0.25, 0.5% Inj;
Not Insured Drugs: Arixtra, Avandamet, Bextra, Zometa;
Products Delisted: Apo-Nefazodone, Gen-Nefazodone, Lin-Nefazodone, Novo-Nefazodone, pms-Nefazodone, Serzone-5HT;
New Interchangeable Products and Updated MAC List: See Bulletin for details;
Criteria for requesting ChEI a Functional Assessment Staging (FAST) score must be defined and monitored.
Posted December 1, 2003
Nova Scotia
December 2003 Bulletin
Highlights
Status Change: Risperdal and Seroquel now Full Benefits;
Olanzapine is still Restricted
Posted November 26, 2003
Alberta
Update Bulletin November 2003
Highlights
Quantity Authorizations for Greater than 100 Days Supply for Group 66 (maximum 200 days in one benefit period July 1 to June 30);
Effective November 28, 2003 De-listed Products: Apo-Nefazodone, Don-Nefazodone,Gen-Nefazodone, Lin-Nefazodone, Novo-Nefazodone-5HT2, PmsNefazodone, Serzone 50,100,150,200mg Tabs;
Correction re LCA 60-day Transition Period: Product additions that were listed as new LCA designations in the October 2003 Update, will be recognized at the AAC until December 1, 2003 and NOT December 31, 2003;
New LCA Pricing Category: Cyproterone Acetate, Flutamide, Ipratropium Bromide
Posted November 7, 2003
Québec
Modifications 15th Edition effective November 5, 2003
Highlights
See update bulletin for details.
Posted November 5, 2003
Alberta
Additions effective November 1, 2003
Highlights
New Drug Products Added: Apo-Carvedilol, PMS-Carvedilol 3.125mg, 6.25mg,12.5mg, 25mg Tab, and Co Simvastatin 5mg, 10mg, 20mg, 40mg, 80mg Tab;
New Special Authorization Drug Product: Novo-Alendronate 10 mg Tab
Posted November 4, 2003
Nova Scotia
October 2003 Bulletin effective November 1, 2003
Highlights
New Maximum Allowable Cost for Diazepam 5mg Tab and Actual Acquisition Cost will be paid for Vivol;
New Interchangeable Products: see bulletin;
Discontinued Products: Atarax, Dobutrex, Elavil, Kefzol, Methotrexate, Motrin, Myciguent Oint, Nebcin, Novolin GE Lente Insulin,
Novolin GE Ultralente Insulin, Orudis SR, Paludrine, PanOxyl Aquagel, Phenaphen #3, pms-Cimetidine, pms-Piroxicam, Ponstan, SAS Enteric, Vancocin CP;
DIN Changes: Zinacef
Posted October 31, 2003
British Columbia
Pharmacare Newsletter October 29, 2003
Highlights
Dispensing Fee increase November 1, 2003: $8.60;
LCA Correction: The newsletter dated October 27, 2003 had an incorrect effective date of October 27, 2003.
The new LCA Categories effective November 27, 2003: Bisoprolol Fumerate Tab 5mg, Bioprolol Fumarate Tab 10mg, Calcitonin,Carvedilol Tab 3.125mg, Carvedilol Tab 6.25mg,
Carvedilol Tab 12.5mg, Carvedilol Tab 25mg, Chloral Hydrate, Ketorolac Tromethamine, Paroxetine Hydrochloride Tab 20mg, Paroxetine Hydrochloride Tab 30mg, Salbutamol Sulphate0.4mg/ml;
Status Change: Tylenol with Codeine No. 3 Tab is now a Full Benefit.
Posted October 30, 2003
New Brunswick
Bulletin 579, effective December 8, 2003
Highlights
Interchangeable Product Additions - Please see list for details
Posted October 27, 2003
British Columbia
Pharmacare Newsletter October 27, 2003
Highlights
New Benefits: Apo-Calcitonin Inj, Apo-Ketorolac 0.5% Oph Sol,
Chloral Hydrate-Odan Syrup, Gen-Paroxetine 20,30mg Tab, Pms-Salbutamol 0.4mg/mL Liq, Ratio-Ketorolac 0.5% Oph Sol, Ratio-Paroxetine 20,30mg Tab,
Rhoxal-Bisoprolol 5,10mg Tab;
Non-Benefits: Gen-Paroxetine 10mg Tab, Ratio-Paroxetine 10mg Tab;
Limited Coverage Drugs: Apo-Carvedilol 3.125, 6.25, 12.5, 25mg Tab, Pms-Carvedilol 3.125, 6.25, 12.5, 25mg Tab;
Special Authority: Rhoxal-Estradiol Derm 50, 75, 100;
Drugs Under Review: Xatral, Kineret, Botox, Cipro XL, Plavix, DDAVP, Octostim, Aricept, Concerta, Zyprexa,
Pegasys, Biprel,Preterax, Elidel, Actos, Actonel, Vagifem, Enbrel, Ezetrol, Zrixtratm, Reminyl, Cytovene, Amaryl, Avonex, Avapro,
Xalacom, Keppra, Cozaar, Metadol, Risperdal, Exelon, Vioxx, Crestor, Avandia, Protopic, Ketek, Androderm, Spiriva, Tarka,
Bextra, Diaplex, Zometa; New LCAs - See Update
Posted October 24, 2003
New Brunswick
MAP List October 2003
Highlights
MAP List October 2003 - Please see list for details
Posted October 22, 2003
New Brunswick
Bulletin 578 effective October 21, 2003
Highlights
Regular Benefit Additions: Biaxin XS 500mg, Mirapex 0.5mg, ReQuip 0.25,1,2,5mg;
Special Authorization Additions: Xeloda 150,500mg Tab, Aranesp 10,20,30,40,50,60,80,100,150mcg Syringe;
Comtan 200mg Tab, Gleevec 100mg Cap, Zyprexa 15mg Tab, Advair 25/125mcg, 25/250mcg Inhaler,
Starlix 60, 120,180mg Tab, Aerius 5mg Tab
Posted October 15, 2003
Manitoba
Bulletin # 41 - effective November 15, 2003
Highlights
Price Change for Gen-Clozapine
Posted October 15, 2003
Alberta
Bulletin October 2003
Highlights
Special Authorization Changes to Criteria: Actos 15, 30, 45mg Tab
Posted October 10, 2003
Alberta
Bulletin October 2003
Highlights
New Temporary Benefit effective September 1, 2003: Piperacillin 2g/4g Vial Inj.;
Removal of Temporary Benefit effective December 1, 2003: SAB-Cortimyxin Ophthalmic Ointment
Posted October 7, 2003
Saskatchewan
Bulletin effective October 2003
Highlights
New Full Benefit: Coversyl Plus 4mg/1.25mg Tab;
New Exception Drug Status effective June 12, 2003: Rapamune 1mg Tab, effective October 1, 2003: Nutropin 10mg Vial, Urso 500mg Tab;
New Interchangeable Listings: see bulletin for details;
Modifications to Current Exception Drug Status Criteria effective June 12, 2003: Valcyte 450mg Tab, effective October 1, 2003: Fosamax 10, 70mg Tab, Actonel 5, 35mg Tab,
Duragesic 25, 50, 75, 200ug/hr Transdermal System, Zyprexa 2.5, 5, 7.5, 10, 15mg Tab and 5, 10mg Orally Disintegrating Tab,
Coreg 3.125, 6.25, 12.5, 25mg Tab, Monocor 5, 10mg Tab, Serevent 25ug metered dose inhaler, powder disk, 50ug blister powder, Serevent Diskus 50ug/dose, Foradil 12ug Cap,
Oxeze Turbuhaler 6ug, 12ug dose;
Products Under Review: Gen-Clozapine, Apo-Cyclosporine, Rhoxal-Cyclosporine, Ketk, Cipro XL, Pegasys, Concerta, Keppra, Ezetrol, Elidel;
Not Listed: Tarka Tabs, Spiriva powder capsule 18ug/dose, Vitamin B6 100mg Tab, Folic Acid 1mg Tab, Dom-Cefaclor oral suspension, Palladone CR Caps, Minirin 0.1mg Tab, Zelnorm 6mg Tab, Avandamet Tabs, Arixtra injection solution;
Delisted: Trikacide 500mg Capsule;
Updated Diabetic Supplies List effective July 1, 2003: see bulletin
Posted October 7, 2003
Nova Scotia
October 2003 Bulletin
Highlights
Product Shortage: Lotriderm Cream
(alternative: Hydrocortisone Powder 1-2.5% in Clotrimazole Cream;
Replacement pages for MAC List; New Interchangeable Products: see bulletin.
Posted October 3, 2003
Alberta
Update Effective October 1, 2003
Highlights
Special Authorization Criteria Changes: Actos 15, 30, 45mg Tab
Posted October 3, 2003
Alberta
Update Effective October 1, 2003
Highlights
Addition: Gen-Clozapine 25 and 100mg Tab
Posted September 30, 2003
Québec
Version 15 effective October 1, 2003
Highlights
Additions: Crestor 10, 20, 40 mg, Geb-Clozapine 25, 100mg, Rapamune lmg,
Exception Status: Elidel 1% Top Crm, Spiriva 18mcg, Advair Diskus;
Exception Status Modifications: Avonex, Betaseron, Xeloda, Warfarine, Avandamet, Preterax
Posted September 23, 2003
Alberta
Quarterly Update October 1, 2003
Highlights
New Products Added: Apo-Pimozide 2,4mg Tab, Cefuroxime 1.5g/vial, Diovan 80,160mgTab,
PMS-Lamotrigine 25,100,150mg Tab, ratio-Amoxi Clav 875mg/126mg Tab, ratio-Lamotrigine 25,100mg Tab,
ratio-Methylphenidate 5mg Tab, Rhoxal-Bisoprolol 10mg Tab, Rhoxal-Estradiol Derm 50, 75, 100 Patch,
Rhoxal-Fluvoxamine 50,100mg Tab, Rhoxal-Lavastatin 20,40mg Tab, Vortex device, Votex Baby Whirl Infant Maskdevice,
Vortex Spinner Pediatric Mask device, Vortex Adjust Mask device;
Discontinued Products: Inocid 50,100mg Supp,
Lanoxin 0.25mg/mL Inj, Mortrin 600mg Tab, Nitro-Dur 0.3mg/hr Patch, Novo-Clopamine 10,50mg Tab, Novolin ge Lente 100 Unit/mL Inj,
Novolin ge Ultralente 100 unit/mL Inj, Panoxyl Aquagel 10%, 20%, Pentasa 2g/100mL rectal enema, Ponstan 250 mg Cap, Rovamycine-500, S.S.S.
Enteric 500 mg EC Tab;
Special Authorizations Added: Andriol 40mg Cap, Androderm 12.2, 24.3mg Patch, Arava 10, 20mg Tab, Plavix 75 mg Tab
Posted September 19, 2003
NIHB
Drug Bulletin September 2003
Highlights
Change in Benefit Status: Pariet, 10 mg Tab, Methadone for Opiod Dependency;
Delisted Products: Codeine Containing Cough Preparations (Dimetapp-C Liquid, Ratio-Cotridin Syrup,
Co-Actifed Syrup, Covan Syrup, Co-Actifed Tablets); Nasal Congestion
(Otrivin Drops and Spray, Decongestant Spray, Otrivin MD Pump, Triaminic Oral Infant Drops,
PMS-Pseudoephedrine Oral Liquid, Eltro SR 120mg Tab, Sudafed SR 120mg Tab, Pseudofrin Tab and Syrup, Congest-Eze Tab,
Sudafed Extra Strength Tab, Tantafed Tab); Dental Agents; Antacis and Adsorbents; Antriprurities and Local Anesthetics
(Calamine Lotion, Nupercainal Oint and Crm, Anusol Oint and Supp, Anuzine Oint and Supp, Egozine Supp, Hemorrhoid Oint,
Anusol Plus Oint and Supp; Sunscreen Agents; Emollients (Glaxal Base))
Posted September 9, 2003
Ontario
Drug Programs Branch Bulletin Fall 2003.
Please see the formulary for details.
Highlights
Plavix (Clopidogreal) Review: Limited Use or Section 8; Acute Coronary Syndrome Review, Percutaneous Coronary Interventions: Aggrenox: Limited Use,
Ticlopidine: Limited Use, Acetylsalicylic Acid: Section 8, Entrophen & Generics: Full Benefit; Osteoporosis Review,
Angiotensin II Receptor Blocker Review: Didrocal:
General Benefit; Fosamax and Generic: Limited Use,
Actonel: Limited Use; Evista: Limited Use, Miacalcin: Not Listed;
Nutrition Products Update: Clarification of nutrition product cagegory definitions, Development of a new nutrition product form,
Introduction of a maximum allowable reimbursement mechanism for the pediatric and chemically defined nutrition products,
Clarification of sumbission requirements of manufacturers seeking reimbursement.
Section 8 Enhancements: approval periods have been extended byond one year for certains products used to treat chronic conditions;
new request forms: Plavix and antidiabetic agents such as Actos, Avandia, Diamicron, Gluconorm and Starlix.
Posted September 4, 2003
New Brunswick
Bulletin effective September 3 2003
Highlights
New Special Authorization Drugs: Aricept 5,20mgTab, Reminyl 4,8,12mgTab,
Exelon 1.5,3,4.5,5mgCap and 2mg/mL Oral Liquid
Posted August 25, 2003
British Columbia
Pharmacare Newsletter August 22, 2003
Highlights
New Benefits: Novo-Gabapentin Tab 800mg, Apo-Pimozide Tab 2, 4mg, Methylprednisolone Acetate Inj Susp 40, 30mg/mL;
Methylprednisolone Acetate with preservative Inj Susp 40,80mg/mL, Ratio-Methylphenidate Tab 5mg;
New Limited Coverage: Novo-Alendronate Tab 10mg; Drugs Under Review: Xatral 10mg Tab, Kineret 105mg/mL Inj, Stemgen 1875, 2000mcg/vial,
Botox Inj, Plavix 75mg Tab, DDAVP Tab, Octostim 15mcg/mL Inj, Aricept 5,10mg Tab, Vagifem 25mcg Vag Tab, Enbrel Inj, Ezetrol 10mg Tab,
Neupogen 0.3mg/mL, Reminyl 4,8,12mg Tab, Cytovene 500mg Cap, Amaryl 1,2,4mg Tab, Avapro Tab, Xalacom 50mcg/mL Opth Sol, Keppra 250,500m750mg Tab,
Cozaar Tab, Concerta Tab, Zyprexz Tab, Biprel 4mg/1.25mg Tab, Elidel 1% Crm, Actos 15, 30, 45mg Tb, Risperdl M-Tab 0.5, 1, 2mg OD Tab, Exelon Cap,
Vioxx 25mg Tab, Crestor 10, 20, 40mg Tab, Avandamet, Avandia Tab, Protopic 0.03 0.1% Oint, Ketek 400mg Tab, Androderm 24.3mg Trans Del Sys, Spiriva 18mcg Cap,
Tarka 1/240mg, 2/180mg, 2/240g, 4/240mg Tab, Bextra 10, 20mg Tb, Diaplex, Zometa 4mg Vial
Posted August 18, 2003
Manitoba
Bulletin # 40 - effective September 15, 2003
Highlights
Additions:Amcinonide .1% Top Crm, Apo-Calcitonin 200 IU/mL, Apo-Gliclazide 80mg, Apo-Indapamide 1.25, 2.5mg Tab,
Apo-Ketorolac, .5% Oph Sol, Apo-Pimozide 2,4mg Tab, Biprel 4mg/1.25mg Tab, Co-Clomipramine 10,25,50mg Tab, Crestor 10,20,40mg Tab,
Diamicron 80mg Tab, Diamicron MR 30mg SRT, Diovan, 80,160mg Tab, Diovan HCT 160 mg/25mg Tab, Dom-Indapamide 1.25,2.5mg Tab,
Gen-Clozapine 25,100mg Tab, Gen-Gliclazide 80mg Tab, Gen-Indapamide 1.25, 2.5mg Tab, Lozide 1.25,2.5mg Tab, Nalcrom 100mg Cap,
Novo-Gliclazide 80mg Tab, Novo-Indapamide 2.5mgTab, Nu-Indapamide 2.5mg Tab, Palladone XL 12,16,24mg CRC, pms-Indapamide 1.25,2.5mg Tab,
QVAR 50,100mcg/dose INH, ratio-Gliclazide 80mg Tab, ratio-Indapamide 1.25,2.5mg Tab, Ratio-Pravastatin 10,20,40mg Tab,
Rhoxal-fluvoxamine 50,100mg Tab, Rhoxal-lovastatin 20,40mg Tab, Rhoxal-metformin FC 500,850mg Tab, Sustiva 600mg Tab, Valcyte 450mg Tab,
Xalacom 50mcg/mL Oph Sol, BFD Latitude Test Strip, FreeStyle Blood Glucose Test Strip, Precision Easy Test Strip, Owen Mumford Unifine Pentips 6,8, 12mm Pen Needles,
UltiCare 30 and 29 Gauge Syringe;
Special Authorization Amendments: Actonel 35mg Tab, Novo-Alendronate 10mg Tab, ratio-Amoxi Clav 875/125mg Tab, ratio-Methylphenidate 5mg Tab,
Rhoxal-estradiol derm 50,75,100mcg Pat,
Change to Full Benefit: Nalcrom 100mg CAP;
New Special Authorization: Amaryl 1,2,4mg Tab, Apo-Cyclosporine 100mg/mL Sol, Arixtra 2.5mg Inj, Exelon 2mg/mL O/S, pms-Tryptophan 500mg Cap, Rapamune 1mg Tab,
Rhoxal-cyclosporine 100mg Cap, Unidet 2,4mg ERC;
Not Recommended: pms-Oxycodone-Acetaminophen 5mg Tab, Tarka 1,2,4mg Tab, Vexol 1% Oph Sus, Zelnorm 6mg Tab;
New Interchangeable Products and Product Price Changes: Please see Bulletin for Details;
Deletions: Avloulfon 100mg Tab, Desoxi .5% Cream and Gel, Novo-Nidazol 250mg Tab, Glucagon 1mg/mL Inj;
Discontinued Products: Apo-Dipivefrin, Apresoline, Colchicine, Cytadren, Desoxi, Ergamisol, Gynergen, Hygroton, Isotrex, Lamisil, Locasalen, Ludiomil,
Mellaril, Mesantoin, Metandren, Mycostatin, Nitro-Dur, Novo-Keto-EC, Novo-Triolam, Novo-Tripramine, Novo-Veramil, Oyster Shell Calcium, Panoxyl Aquagel, Pentasa,
Pertofrane, Rho-fluphenazine, Rho-haloperidol, Rimactane, Rovamycine, S.A.S., Serentil, Serpasil, Tofranil, Torecan, Transderm-Nitro, Trasicor,
Vioform HC and Mild
Posted August 14, 2003
Newfoundland
Benefit Listing effective August 8, 2003
Highlights
Please see listing for details.
Posted August 11, 2003
Ontario
FORMULARY EDITION NO. 38, Update B - effective September 4, 2003
Highlights
Product Additions: Cortef 10 mg Tabs; Crestor 10, 20 and 40 mg Tabs; Diovan 80 and 160 mg Tabs; Diovan-HCT 160mg/25mg Tab;
NovoRapid 100U/mL Inj Sol-5x3mL Pk and Sol-10mL Pk; Palladone XL 12, 16, and 24 mg CR Caps; Plavix 75mg Tabs; Spiriva 18mcg Cap; Sustiva 600mg Tabs; Zyprexa 15mg Tabs;
Multisource: Apo-Amoxi Clav 875mg & 125mg Tabs; Apo-Hydroxyquine 200mg Tab ; Apo-Lithium Carbonate 150 and 300mg Caps;
Co-Clomipramine 10, 25, 50 mg Tabs; Gen-Sertraline 25, 50 100 mg Caps; Novo-Alendronate 10mg Tabs;
Novo-Pravastatin 10, 20, 40 mg Tabs; Novo-Ticlopidine 250mg Tabs; PMS-Fluconazole-150 150mg Caps;
Ratio-Amoxi Clav 875mg & 125mg Tabs; Ratio-Pravastatin 10, 20 and 40 mg Tabs; Ratio-Timolol Maleate 0.5% Oph Sol;
Rhoxal-Bisoprolol 5 and 10 mg Tabs; Rhoxal-Fluvoxamine 50 and 100 mg Tabs;
Rhoxal-Lovastatin 20 and 40 mg Tabs; Rhoxal-Metformin FC 500 mg Tab; Rhoxal-Sertraline 25, 50 and 100 mg Caps.
Discontinued By Manufacturer: Apo-Dipivefrin 0.1% Oph Sol; Codeine 15, 30, and 60 mg Tabs;
Ergamisol 50mg Tabs; Grisovin FP 125 and 500 mg Tabs; Halotestin 5 mg Tabs;
Iletin II Lente 1000U/10mL Inj Susp-10mL Pk; Metandren 10 and 25 mg Tabs; MS-IR 10, 20, and 30 mg Sup;
Novolin ge 30/70 Penfill 100U/mL Inj Susp-5x1.5 Pk; Novolin ge NPH Penfill 100U/mL Inj Susp-5X1.5 Pk;
Novolin ge Toronto Penfill 100U/mL Inj Sol-5X1.5 Pk; Panoxyl Aquagel 10% Gel; Pentasa 2g/100mL Enema;
Sodium Bicarbonate 300 and 600 mg Tabs.
New Drug Identification Number(s): 02220385 10-Benzagel 10% Gel; 02147793 Klean-Prep Pd-1 Kit;
02147831 Normacol 62% W/W Gran 1 Sach Pk; 02242374 Pancrease 4000 & 20000 & 25000 USP Units Ent Microsph Caps;
01989553 Rythmodan 100 mg Caps; 01989561 Rythmodan 150 mg Caps.
Not-A-Benefit Drug(s): Amoxil 250 and 500 mg Caps; Codeine 5mg/mL O/L; Dyazide 25mg & 50mg Tabs;
Isordil 5 mg SL Tabs; Isordil 30 mg Tabs; Loxapac 50 mg Tabs; Tagamet 300, 400, and 600 mg Tabs.
Note(s)Removed: Actonel 5 and 35 mg Tabs.
Discontinued Drug(s) (Removed From Payment):Albert-Docusate 240 mg Caps;
Alti-Amiloride HCTZ 5mg & 50mg Tabs; Alti-Bromazepam 1.5 and 3 mg Tabs;
Alti-Mexiletine 100 and 200 mg Caps; Alti-Moclobemide 300 mg Tabs;
Alti-Piroxicam 10 and 20 mg Caps; Alti-Prazosin 1 mg Tabs;
Alti-Ticlopidine 250 mg Tabs; Antabuse 250 mg Tabs; Aristocort 2 mg Tabs;
Asmavent 1mg/mL Inh Sol-2.5mL Pk; Avlosulfon 100mg Tabs; Bisacolax 10 mg Sup;
Chlorpromanyl 20 20mg/mL O/L; Clobetasol Propionate 0.05% Cream, Ointment, and Scalp Solution;
Deproic 250mg Cap; E-Pilo 4 4% & 1% Oph Sol; Ferrous Gluconate 300 mg Tabs; Flurbiprofen 50mg Tabs;
Folic Acid 5mg Tabs; Gen-Fluvoxamine 50 and 100 mg Tabs; Glycerin 1.8 and 2.7 g Sup;
Inderide 40-40 mg & 25mg, and 80-80 & 25 mg Tabs; M.O.S. 10, 20, and 30 mg Sup; Novo-Ampicillin 25mg/mL and 50 mg/mL O/L;
Novo-Baclofen 10 mg Tabs; Novo-Baclofen 20 mg Tabs; Novo-Butamide 500 mg Tab; Novo-Dipam 2, 5, and 10 mg Tabs;
Novo-Doparil-15 250mg & 15mg Tab; Novo-Doparil-25 250mg & 25mg Tab; Novo-Flupam 15 and 30 mg Caps;
Novo-Folacid 5 mg Tabs; Novo-Furan 5 mg/mL O/L; Novo-Furan 50 and 100 mg Tabs;
Novo-Hexidyl 2 and 5 mg Tabs; Novo-Medopa 125, 250, and 500 mg Tabs; Novo-Mucilax Oral Pd;
Novo-Mucilax Sugar Free Oral Pd; Novo-Pen-500 500000IU Tabs; Novo-Poxide 5, 10 and 25 mg Caps;
Novo-Pramine 10, 25, and 50 mg Tabs; Novo-Pyrazone 100 and 200 mg Tabs; Novo-Quinidin 200mg Tabs;
Novo-Ridazine 2mg/mL O/L; Novo-Ridazine 10, 25, 50 and 100 mg Tabs; Novo-Rythro Estolate 250 mg Cap;
Novo-Tetra 250 mg Cap; Novo-Thalidone 50 and 100 mg Tabs; Novo-Tolmetin 400 mg Cap;
Novo-Trifluzine 2, 5 ad 10 mg Tabs; Novo-Triptyn 10 and 50 mg Tabs; Novo-Zolamide 250 mg Tab;
Novoxapam 10, 15, and 30 mg Tab; Phospholine Iodide 0.06% Oph Sol;
Pilocarpine Hydrochloride 1%, 2% and 4% Oph Solutions; PMS-Metronidazole 250 mg Tabs;
PMS-Thioridazine 10, 25, 50, and 100 mg Tabs; Potassium-Rougier 1.33mEq/mL O/L;
Regulex 100mg Caps; Rouphylline 10mg/mL O/L; Schein Nifedipine PA 10 and 20 mg LA Tabs;
Scheinpharm Amoxicillin 250, 500 mg Caps; Scheinpharm Atenolol 50 and 100 mg Tabs;
Scheinpharm B12 1mg/mL Inj Sol-10mL Pk; Scheinpharm Ceclor 250 and 500 mg Caps;
Scheinpharm Clotrimazole 10mg/g Cr; Scheinpharm Gemfibrozil 300 mg Cap;
Scheinpharm Gentamicin 0.3% Oph Sol; Scheinpharm Pilocarpine 1%, 2%, and 4% Oph Sol;
Tobramycin 80mg/2mL Inj Sol-2mL Pk; Tolectin DS 400 mg Cap; Trasylol 100000KIU/10mL Inj Sol-10mL Pk;
Triazolam 0.125 and 0.25 mg Tab; Trilisate 293 mg & 362 mg Tab;
Verapamil 80 and 120 mg Tabs.
New Product Identification Number(s):
Gen-Sertraline 25mg Cap; Gen-Sertraline 50mg Cap;
Gen-Sertraline 100mg Cap; Rhoxal-Sertraline 25mg Cap;
Rhoxal-Sertraline 50mg Cap; Rhoxal-Sertraline 100mg Cap
Limited Use Changes: Tamiflu 75 mg Cap.
Trade Name Change:Pancrease 4500 & 20000 & 25000 USP Units SR Cap.
Change(s) to Diabetic Testing Agent(s): Freestyle - Strip; Precision Easy - Strip.
Change(s) to Nutrition Product(s):Nestle Nutren VHP Fibre 1.0kcal/mL Liq-250mL Pk;
Nestle Nutren VHP Fibre 1.0kcal/mL Liq-1500mL Pk; Pediasure Plus with Fibre 1.5kcal/mL Liq-235mL Pk;
Resource Diabetic 1.06kcal/mL Liq-250mL Pk.
Posted July 17, 2003
Nova Scotia
July 2003 Bulletin
Highlights
Revised MAC List: effective August 1, 2003;
Discontinued Products: Betnesol Pellets, Desoxi .05,.25% Cr, .05%Gel, Ergamisol 50mg Tab, Halotestin 5mg Tab,
Iletin Lente II Pork Insulin, Indocid 50mg, 100mg Supp, Locasalen Oint, Metandren 10mg, 25mg Tab,
Nitro-Dur .3mg/hr Patch, Nolvadex 10mg Tab, PanOxyl Aquagel 10% Gel, Parafon Forte C8 Tab, pms-Flutamide 250mg Tab, pms-Piroxicam 20mg Cap,
Ratio-Cimetidine 300mg, 400mg, 600mg Tab, ratio-Deproic 50mg/ml Syr, Ratio-Desipramine 75mg Tab,
ratio-Ipratropium 21mcg Nas, ratio-Naproxen 375mg, 500mg Tab, Rebetron Inj/Cap, Rhoxal-Fluphenazine 25mg/100mg/mL Inj, Rovamycine 500mg Cap,
Taro-Carbamazepine CR 400mg Tab, Testosterone Propionate 100mg/mL Inj;
DIN Changes: Parafon Foret Tab, ratio-Lactulose 667mg/mL O/L
Posted July 14, 2003
Saskatchewan
Formulary Fifty-third Edition (hard copy)July 2003-July 2004
Highlights
Important Note: Crestor is a FULL BENEFIT LISTING (all three strengths) under the Saskatchewan drug benefit formulary effective July 1, 2003.
Posted July 4, 2003
NIHB
Summer 2003 Update
Highlights
New Limited Use Benefits: Fosamax 70mg Tabs, Actonel 35mg Tab;
New Additions effective December 1, 2002: Soframycin .5% Ophth Sol,
Effective January 1, 2003: Apo-Hydroxyquine 200mg Tab, Apo-Simvastatin 5, 10, 20, 40, and 80mg Tab,
Co-Temazepam 15, 30mg Cap, FXT 40mg Cap;
Effective February 1, 2003: Accu-ChekCompact Test Strips, Apo-Methazolamide 50mg Tab, Enemol 60, 160mg/ml RectalLiquid,
Gen-Nefazodone 50, 100, 150, 200mg Tab, Gen-Simvastatin 10, 20, 40mg Tab,
Gen-Warfarin 2, 2.5, 4, 5, 20mg Tab, Lamictal 2mg Tab, Novo-Lovastatin 20, 40 mg Tab,
Novo-Pravastatin 10, 20, 40mg Tab, One Touch Ultra Test Strips, PMS-Carbamazepine 100,
200mg Chewtabs, Ratio-Sertraline 25, 50, 100mg Cap, Sertraline 25, 50, 100mg Cap;
Effective March 1, 2003: Apo-Cyclosporine 100mg/ml Sol, Gen-Simvastatin 5, 80mg Tab, Lovenox HP 120, 150mg/ml Inj,
Sodium Aurothiomalate 10, 25, 50mg/ml Inj, Testosterone Cypionate 100mg/ml Inj;
Effective April 1, 2003: Dom-Terazosin 1, 2, 5, 10mg Tab, Morphine Sulfate 2mg/ml Inj; Oesclim 10, 5mg Patch,
Rhoxal-Metformin 850mg Tab, Thyrogen .9mg/ml Pow, Valcyte 450mg Tab;
Effective May 1, 2003: Apo-Amoxi-Clav 875, 125mg Tab, Apo-Indapamide 1.25mg Tab, Apo-Ipravent .03%, .06%
Nasal Spray, Gen-Combo Sterinebs .2, 1mg Inh Sol, Nizatidine 150, 300mg Cap,
PMS-Amoxicillin 500, 250mg Cap and 25, 50mg/ml Suspension, PMS-Atenolol 25mg Tab,
PMS-Bimonidine .2% Ophth Sol, PMS-Fluconazole 150 Cap, PMS-Medroxyprogresterone 2.5, 5, 10mg Tab, PMS-Norfloxacin 400mg Tab,
Riva-Ranitidine 150, 300mg Tab, Sustiva 600mg Tab;
Effective July 1, 2003: Apo-K 8mmol Tab, Euro-K 8mmol Cap, Micro-K Extencaps 8, 10mmol Cap, Pro-K 8mmol Tab and Cap, Slow K 8mmol Tab;
Discontined by Manufacturer and Replacement DINs: See Bulletin;
New Special Formulary for Chronic Renal Failure Patients: See Bulletin for details.
Posted July 2, 2003
Nova Scotia
Special Bulletin June 2003
Highlights
Drugs to treat Alzheimer Disease have been added as exception drug benefits.
This incudes all of the cholinesterase inhibitors now the market including Aircept,
Reminyl, and exelon. For further details please see Bulletin.
Posted June 30, 2003
Saskatchewan
Bulletin effective July 1, 2003
Highlights
New Exception Drug Status: Kineret, 100mg/0.67mL;
New DosageForms/Strengths of Exception Drug Status: Actonel 5mg, 35mg;
New Full Formulary Listings: Xalacom 2.5mL, Precision Easy Strip, Benzamycin 3,5% Gel,
Diovan HCT 160mg/25mg, Diovan, 80, 160mg Tab;
New Interchangeable Listings: Please see formulary;
Modifications to Exception Drug Status Criteria: Mobicox 7.5, 15mg Tab, Fosamax, 10, 70mg Tab, Actonel 5, 35mg Tab, Dixarit 0.025mg Tab,
Protopic, 0.03%, 0.1% Ointment, Plavix, 75mg Tab, Ticlid, Apo-Ticlopidine, Nu-Ticlopidine, Gen-Ticlopidine, pms-Ticlopidine, Dom-Ticlopidine,
Rhoxal-Ticlopidine, Novo-Ticlopidine 250mg;
Under Review: Palladone 12, 16, 24mg SR CAP, Apo-Cyclosporine 100mg/mL, Rhoxal-Cyclosporine, 100mg CAP, Bextra, 10, 20mg Tab, Crestor 10, 20, 40mg,
Gen-Clozapine 15, 100mg Tab, Avandamet 1, 2, 4mg Tab, Rapamune 1mg Tab, Spiriva, 18ug/dose Powder Capsule;
Manufacturer Short Supply: Aristospan 20mg/mL, Stilboestrol .1mg, .5mg, 1mg Tab
Posted June 27, 2003
New Brunswick
Formulary Volume 45 Product Updates, effective June 2003
Highlights
New Prescription Drug Formulary: see formulary for datails;
Inerchangeable Additions: 20 drug products added (please see formulary for details);
Claims for products that are reimbursed at Actual Acquisition Cost up to August 3, 2003 will be subject to a Maximum Allowable Price effective August 4, 2003.
Posted June 26, 2003
NIHB
Drug Bulltin July 2003
Highlights
Open Benefit Additions effective April 1, 2003: Thyrogen .9mg/ml, Valcyte 405mg Tab;
Change in Benefit Status effective April 1, 2003: Plavix 75mg Tab - Open Benefit; Potassium Oral Solid Dosage Form;
New Limited Use Benefit effective April 1, 2003: Gleevac 100mg Cap, Fosamax 70mg Tab, Actonel 35mg Tab;
Additions to Special/Fromulary for Crhonic Renal Failure effective April 1, 2003: Aranesp 10, 20, 30, 60, 150mcg;
Not Recommended for Listing: Zelnrom 6mg Tab, Zoledronic Acid, 4mg Inj, Zometa 5mg Inj, Arixtra 2.5mg Inj.
Posted June 25, 2003
Alberta
Quarterly Update July 1, 2003
Highlights
New Products Added: Crestor, Biprel, Estradot, Arixtra (effective June 1, 2003),
PMS-Atenolol;
New Special Authorization: Actonel 35mg, Androderm 5mg; Exelon, 2mg/ml;
Deferred Product: Kineret;
Product Not Added: Bextra:
New Interchangeable Products: Apo-Lithium Carbonate;
Marketing Study for Enbrel and Remicade announced
Posted June 25, 2003
Newfoundland
Interchangeable Drug Update effective June 24, 2003
Posted June 20, 2003
Newfoundland
New version of the formulary effective June 2003
Posted June 18, 2003
British Columbia
PharmaCare Coverage Criteria Change for Proton Pump Inhibitors effective July 15, 2003
Highlights
Effective July 15, 2003 PharmaCare will require patients who qualify for Special Authority
coverage of PPIs to try treatment with Pariet first.
If long-term PPI treatment is required the Special Authority for that particular
PPI will remain in effect until its usual expiry date or until January 14, 2004
whichever comes first. For more details see Bulletin.
Posted June 16, 2003
Nova Scotia
Pharmacare June 2003 Bulletin
Highlights
New Exception Drug Status Criteria: Duragesic;
New Exception Status: Pegetron 200mg CAP, Valcyte 450mg Tab, Humatrope 1mg, 6mg Inj, 12mg Vial,
Nutropin AQ 10mg Inj, Nutropin 5mg, 10mg Vial, Saizen 3.33mg, 5mg Vial, Symbicort 100/200 Turbuhaler,
Actonel 35mg Tab;
Maximum Allowable Cost removed effective June 15, 2003: Desoximetasone;
New Products Added: FXT 40 40mg CAP, pms-Atenolol 25mg Tab, Xalacom Oph Sol, Precision Easy Tst Strips,
Not Listed: Amaryl, Kineret, Zelnorm
Posted June 12, 2003
New Brunswick
New MAC Price List is now available June 2003
Posted June 12, 2003
British Columbia
Pharmacare Newsletter June 6, 2003
Highlights
Eligible Benefits (Plans B, C, F, I): NovoRapid Inj 10ml vial (maximum allowable price of $1.9625/ml,
Mavik Tabs 1, 2, 4mg (reference product for ACE inhibitor category), Gen-Clozapine Tab 25 and 100mg,
Ratio-Amosi Clav Tab 125mg, Amcort Cream .1%;
Non-Benefits: Xatral Tab 10mg, Lumigan Drops .03%, Tequin, Tab 400mg, Protopic ointment .03 and .1%, Zelnorm Tab 6mg,
Arixtra Subcutaneous Solution 2.5mg/0.5ml, Aggrenox CAP 200mg/25mg, Mucillium Powder, Precision Xtra Blood Ketone Test Strips;
New LCA and/or RDP Drugs: Co Clomipramine, Pms-Tryptophan, Ratio-Pravastatin, Rhoxal-Fluvoxamine, Rhoxal-Lovastatin;
New LCA Categories: AmoxicillinClavulanate tab, Amcinonide Cream;
Limited Coverage Drugs: Actonel Tab 35mg, Nutropin Inj 10mg, Teveten Tab 600mg, Zyprexa Tab 15mg, Nasonex Nasal Spray 50mcg,
Estrodot Patches, Estalis Patch, Estalis-Sequi Patch;
Drugs Under Review: Kineret, Stemgen, Botox, Plavix, DDAVP, Octostim, Aricept, Hectorol, Vagifem, Neupogen,
Cytovene, Avapro, Xalacom, Cozaar, Zyprexa, Trileptal, Pegetron, Biprel, Elidel, Exelon, Vioxx, Crestor, Avandamet, Avandia,
Androderm, Spiriva, Tarka, Bextra, Diaplex, Zometa
Posted June 2, 2003
Québec
Version 14 effective June 2003
Highlights
Additions: Actonel, Apo-Hydroxyquine, Biprel, Palladone, Declined due to therapeutic value: Minirin, Xalacom,
Declined due to price accuracy: Bextra,
Exception Status: Cancidas, Coaguhek;
Modified Exception Criteria: Gleevec, Pegetron, Rebetron, Unitron-Peg,
Plavix, Xeloda, Zyvoxam,
Posted May 27, 2003
Alberta
Additions effective June 1, 2003
Highlights
New Addition: Arixtra .5ml syringe
Posted May 26, 2003
New Brunswick
Bulletin effective May 26, 2003
Highlights
Special Authorization Additions May 26, 2003: Fosamax 70mg tab, Xeloda 150/500mg tab, NovoRapid 100vial, Remicade 100mg inj.;
Effective April 1, 2003: Remicade 100mg inj., Enbrel 25mg inj., Pariet, 10mg tab,
Drugs Not Listed May 26, 2003: Protopic, .03% and .01% oint., Dovobet, 50mcg/g oint.
Posted May 14, 2003
Saskatchewan
News Release May 1, 2003 Effective July 1, 2003
Highlights
Diabetic Supplies, Nutritional Supplements will be added to the Drug Plan and will
be covered in the same manner as Insulin, type II diabetic drugs and blood glucose
test strips are already.
Posted May 13, 2003
Nova Scotia
May Bulletin effective May 1, 2003
Highlights
Proton Pump Inhibitors Policy Changes effective June 1, 2003;
New Exception Status Benefit: Pariet
Posted May 8, 2003
New Brunswick
Bulletin 562, May 6, 2003
Highlights
Note: Claims for products that are reimbursed at Actual Acquisition Cost up to June 19, 2003 will be subject to a Maximum
Allowable Price effective June 20, 2003.
All interchangeable products in New Brunswick for purposes of Special Authorization will have MAP applied.
New Interchangeable Product Additions: please see bulletin for details.
Posted May 6, 2003
Nova Scotia
May Bulletin effective May 15, 2003
Highlights
Appendix IV Criteria for Coverage of Exception Stuats Drugs has been completely updated to reflect recent changes.
Please see Appendix for details.Changes to Maximum Allowable Cost List effective May 15, 2003.
Numerous Discontinued Products (see Bulletin for details) and DIN Changes for Levophel 1mg/ml and Neo-Synephrine 10mg/ml
Posted April 25, 2003
Manitoba
Bulletin #39 Amendment
Highlights
New interchangeable products, interchangeable product price changes, category deletion: Please see the bulletin
Part 2 Addition/Amendment: Novo-Fluconazole-150
Posted April 24, 2003
Manitoba
Bulletin #39 - effective May 1, 2003
Highlights
Additions: Advair, Apo-Flavoxate, Apo-Hydroxyquine, Apo-Ipravent, Apo-Methazolamide, Apo-Metoprolol,
Apo-Nitrazepam, Apo-Salvent CFC Free, Apo-Selegiline, Apo-Simvastatin, Apo-Trimebutine,
Apo-Zopiclone, CO Temazepam, Eldepryl, FXT 40, Gen-Combo Sterinebs, Gen-Nefazodone, Gen-Nizatidine,
Gen-Selegiline, Gen-Simvastatin, Glucagon, Kadian, Lumigan, Micardis Plus, Novo-Lovastatin,
Novo-Nefazodone-5HT2, Novo-Pravastatin, NovoRapid, Novo-Selegiline, Nu-Selegiline, pms-Amoxicillin,
pms-Atenolol, pms-Brimonidine, pms-Carbamazepine Chewtabs, pms-Clobazam, pms-Erythromycin, pms-Flavoxate,
pms-Lovastatin, pms-Medroxyprogesterone, pms-Selegiline, Premplus, PrimeAire, Quinine, ratio-Brimonidine,
ratio-Ipra Sal UDB, ratio-Lamotrigine, ratio-Lovastatin, ratio-Sertraline, ratio-Zopiclone, Remeron,
Rho-nitro Pumpspray, Rosasol, Seroquel, Symbicort 100 and 200, Travatan, Trizivir, Vagifem, Videx EC, Xatral,
Zyprexa;
Exception Drug Amendments: Apo-Amoxi Clav, Apo-Flunarizine, Apo-Tobramycin, Biaxin, Biaxin XL, Estalis-Sequi,
Estradot, Fosamax, Gen-Fluconazole, Novo-Fluconazole-150, Novo-Fluconazole, Novo-Ticlopidine, Pariet, pms-Fluconazole,
pms-Norfloxacin, ratio-Amoxi Clav 125 F, ratio-Amoxi Clav 250 F, ratio-Amoxi Clav 250, ratio-Amoxi Clav 500,
ratio-Methylphenidate, Singulair, Tequin;
Deletions: Alti-Salbutamol, Apo-Salvent, Novo-Salmol; Ventolin 100mcg;
Apo-Selegiline, Eldepryl, Gen-Selegiline, Novo-Selegiline, Nu-Selegiline,
pms-Selegiline; Exception Status Adds: Pamidronate Disodium, Apo-Lactulose,
Laxilose, pms-Lactulose, ratio-Lactulose, Serc, Spo-Gliclazide, Apo-Indapamide,
Aranesp, Ditropan XL, Evista, Gleevec, Lactulose, Lovenox HP, Pamidronate Disodium,
Pegetron, pms-Butorphanol;
Criteria Changes: Betaseron, Miacalcin;
Special Consideration Process: Enbrel, Kineret, Remicade;
Not Listed: AndroGel, Androderm, Carnitor, Clindoxyl, Dovobet, Florazole ER,
Meridia, Nexium, Rilutek, Santyl, Thyrogen, Xenical;
Interchangeable Updates: See the Bulletin for details;
Product Deletions: Asendin, Fexicam, Inderal, Inflamase mild, Isordil,
Neptazane, Novo-Timol, Orudis, Orudis E-50, Roxicet;
Manufacturer Product Deletion: Alti-Beclomethasone, Apo-Zidovudine, Novo-AZT,
Empracet-30,Empracet-60;
Manufacturer Product Discontinuation: Aldomet, Alti-Amiloride HCTZ, Cephulac, Caltine, Choledyl SA,
Chronulac, Cogentin, Cortisporin, Cortone, Decadron, Diamox, Diodex, Diogent,
Diopred, Diosulf, Elavil, Feldene, IMAP, IMAP Forte, Intal, Loxapac, Mavik, Mefoxin,
Micro K-10, Moditen, Moditen Enanthate, Modulon, Nitrong SR, Novogesic C-8/C-15/C-30,
Novo Hydrocort, Purinol, Pyridium, Teveten, Ulcidine, Urecholine, Vivol+D24
Posted April 16, 2003
Saskatchewan
Saskatchewan Update effective April 1, 2003
Highlights
Exception Status Drugs: Pegetron, Valcyte;
New Exception Status Drug Strengths: Sustiva 600mg, Estradot 25ug;
Full Benefit Listing: BD Latitude, Quinine SO4, Atenolol;
Change in Status: Seroquel becomes a Full Benefit;
Changes to Exception Status Criteria: Evista, Remicade, Enbrel, Estrogel, Estraderm, Vivelle, Climara, Oesclim,
Estradiot, Estalis, Estalis-Sequi, Estracomb;
Not Recommended: Florazole ER, Androderm, Thyrogen, Zelnorm, Arixta;
Under Review: Apo-Cyclosporine, Rhoxal-Cyclosporine, Bextra, Xalacom, Apo-Hydroxyquine, Crestor, Gen-Clozapine;
Delisted Products: Cefaclor, Detrol.
Posted April 8, 2003
British Columbia
Pharmacare Newsletter April 8 2003
Highlights
Effective May 1, 2003 reimbursement for vitamins and nutritional supplements covered
under the Pharmacare plans for eligible cystic fibrosis patients will change.
These products will be adjudicated at the Actual Acquisition Cost plus the dispensing fee.
Posted April 1, 2003
NIHB
Spring 2003 Update
Highlights
Limited use Benefits: Fosamax, Xatral, Agenerase, Tantum, The Magic Bullet, Botox,
Wellbutrin SR, Zyban, Dostinex, Miacalcin, Celebrex, Cipro HC Otic, Codeine Contin,
Aggrenox, Symbicort, Hydromorph Contin, Gleevec, Rebetron, Prevacid, Arava, Carnitor,
Kaletra, Mobicox, Minocin, Singulair, Pre-Natal and Pediatric Multivitamins,
Nicorette, Habitrol, Nicoderm, Nicotrol, Losec, Oxycontin, Pantoloc, Actos, Pariet,
Evista, Actonel, Vioxx, Avandia, Advair, Rapamune, Protopic, Flomax, Temodal,
Zanaflex, Detrol, Unidet, Visudyne, Accolate;
Discontinued Products: Multiple manufacturer discontinued products - see formulary for details;
Additions: Effective Dec. 1, 2002: Soframycin, Effective Jan. 1, 2003: Apo-Hydroxyquine, Apo-Simvastatin, Co-Temazepam, FXT 40,
Effective Feb. 1, 2003: Accu-Chek Compact Test Strips, Apo-Methazolamide, Gen-Nefazodone, Gen-Simvastatin, Gen-Warfarin, Lemictal,
Novo-Lovastatin, Novo-Pravastatin, One Touch Ultra Test Strips, PMS-Carbamazepine, Ratio-Sertraline, Sertraline
Posted April 1, 2003
Nova Scotia
Dispensing Fee Increase 3 April 1, 2003
Highlights
Prescriptions costing $130 or less: $9.54 dispensing fee;
Prescriptions costing more than $130: $14.31 dispensing fee.
Posted April 1, 2003
Alberta
Health & Wellness Update effective April 1, 2003
Highlights
New Special Authorization Drugs: Enbrel, Remicade
Posted April 1, 2003
Alberta
AHWDBL Update April 2003
Highlights
New Products Added: Apo-Clobazam, Apo-Flunarizine, Apo-Indapamide, Apo-Metoprolol, Apo-Nitrazepam, Apo-Salvent CFC Fee,
Apo-Tobramycin, Apo-Trimebutine, Apo-Warfarin, FXT 40, Gen-Nefazodone, Lumigan, Novo-Nefazodone, Novo-Ticlopidine, PMS-Amoxicillin,
PMS-Fluconazole, PMS-Medroxyprogesterone, PMS-Norfloxacin, ratio-Lactulose, TOBI,
Zyprexa;
Deferred Products: Zometa;
Declined Products: Amaryl, Benzamycin, Tarka, Xalacom;
Changes to Special Authorization Criteria: Nitoman, Apo-Cyclosporine, Evista, Neoral, Rhoxal-Cyclosporine;
New Special Authorization Products: Andriol, Unidet, Pegetron;
Discontinued Special Authorizations: Alertec, Berotec, Flovent, PEG-Intron, Rebetron, Zanaflex;
De-listed Special Authorization: Detrol;
Discontinued Products: See update for details
Posted March 21, 2003
Ontario
Formulary Edition No. 38 - Update A - effective April 16, 2003
Please see the formulary for details.
Highlights
Product Additions: Actonel, Clindoxyl, Comtan, Premplus, Tamiflu, Thryriogen,
Valcyte, Apo-Cyclosporine, Apo-Indapamide, Apo-Nitrazepam, Apo-Simvastatin,
Co-emazepam, Gen-Fluconazole, Gen-Nefazodone, Gen-Simvastatin, Nove-Fluconazole, Novo-Lovastatin,
Novo-Nefazodone-5HT2, PMS-Carbamazepine, PMS-Medroxyprogessterone, PMS-Norfloxacin,
Ratio-Amoxi Clav, Ratio-Brimonideine, Ratio-Lamotrigine, Ratio-Sertraline, Taro-Carbamazepine;
Discontinued Products: Apresoline, Beclomethasone Dipropionate, Cafergot-PB, Caltine, Colchicine, Diamox, Feldene,
Glucagon Inj. Pd, IMAP, IMAP Forte, Intal Inh, Modditen Enanthte, Norplant sytem Kit, Novo-Chlorpromazine, Novo-Clopamine,
Novo-Desipramine, Novo-Keto, Novo-Maprotiline, Novo-Meprazine, Novo-Nidazol, Novo-Salmol, Novo-Triolam, Novo-Tripramine,
Novo-Veramil, Phenobarbital, Pyridium, Ulcidine, Vitamin A (NOP);
New Drug Identification Number(s):00436895 Koffex 3mg/mL O/L;
Delisted Nutrition Products: IsoSource Liquid, NutriSource HN Liquid;
Limited Use Changes: Actonel, Arimidex, CellCept, Evista, Exelon, Femara, Fosamax;
Nutrition Product Changes: Jevity, Osmolite, Peptinex, Resource Liquid, Resource Plus Liquid;
Multipe Price Changes: see the update for details;
Manufacturer Name Changes: see the update for details,
New Trade Names and DINs: See the update for Details
Posted March 19, 2003
British Columbia
Pharmacare Newsletter March 2003
Highlights
Dispensing Fee increase April 1, 2003: $8.50;
New PINs assigned for Colostomy and Ostomy products;
New Blood Glucose Test Strips added: BD Latititude and Precision Easy;
Status Change: Limited Coverage goes to Full Benefit: Glucagon;
New Full Benefits: Apo-Hydroxyquine (220mg), Pms-Atenolol (25mg);
LCA Updates: See Update for Details;
New Limited Coverage Drugs: Apo-Ipravent Nasal Spray, Pamidronate Disodium;
Drugs Under Review: Kineret, Stemgen, Xatral, Lumigan, Botox (new indication), Plavix (new indication),
DDAVP (resubmission), Octostim, Aricept (resubmission), Teveten (resubmission),
Neupogen (new indication), Arixtra, Amaryl, Avapro (new indication), Axmax Twisthaler (resubmission), Zyprexa (new strength),
Pegetron, Biprel, Gluconorm (resubmission), Exelon (resubmission), Crestor, Protopic, Vagifem, Zelnorm, Androderm,
Spiriva, Mavik (resubmission), Tarka, Bextra
Posted February 28, 2003
Nova Scotia
February 2003 Bulletin
Highlights
Nova Scotial Seniors' Pharmacare Program Changes for 2003-2004 Premium Year (see Bulletin for details);
Denied Coverage for BPH: Flomax, Xatral;
New Criteria Codes for Macrolides: Code 07=Clarithromycin, Code 08=Azithromycin;
Effective March 1, 2003: New Benefits: Apo-Metoprolol, Vagifem;
New Exception Status Benefits: Marinol, Pariet, Plan B, Unidet;
Not Insured: Fucithalmic 1%, Hectorol, Lumigan 0.03%, Xatral, Zaditor;
Interchangeable and MAC List updates: see Bulletin for details.
Posted February 25, 2003
Alberta
Update effective February 1, 2003
Highlights
Due to the shortage of Myochrysine 50mg/ml injection, Sodium Aurothiomalate 50mg/ml injection will be considered a temporary benefit
Posted February 24, 2003
Newfoundland
New version of the formulary effective February 24, 2003
Posted February 17, 2003
Newfoundland
New version of the formulary effective February 17, 2003
Posted February 17, 2003
New Brunswick
Bulletin effective February 14, 2003
Highlights
Benefit Additions: Infufer DexIron, Monocor, Copaxone, Remeron, Glucagon, Kadian;
Revised Special Authorization Criteria: Plavix;
Special Authorization Additions: Vivelle, Estradot, Estalis, Estalis-Sequi, Travatan
Posted February 7, 2003
Québec
Version 13 effective February 2003
Highlights
Additions: Apo-Cyclosporine, Arixtra, Xatral;
Pricing Adjustmen: Florazole;
New Exception Status: Aranesp, Fludara, Tarka, Videx, Pegetron;
Exception Status Modifications: Peg-Intron, Trileptal, Valcyte;
Changed to Exception Status: Rebetron;
Changed to Full Benefit Status: Symbicort;
Delisted: Salbutamol
Posted February 7, 2003
Alberta
Additions to the AH&W Drug Benefit List effective February 1, 2003
Highlights
New Drug Product Added: Apo-Simvastatin;
New Interchangeable Product Affected by LCA: Simvastatin;
New Non-Interchangeable Products: Dexiron, Infufer
Posted February 6, 2003
British Columbia
Pharmacare Newsletter February 4, 2003
Highlights
Salbutamol products containing CFC propellants are no longer eligible for coverage.
CFC-free salbutamol inhalers are available: Apo-Salvent CFC Free Aer inh, Ratio-Salbutamol HFA Aer inh
Airomir Aer inh; New Benefits: Apo-Simvastatin, Apo-Trimebutine, Gen-Simvastatin;
New Drugs Categorized to LCA and/or RDP: Pms-Clobazam, Pms-Oxycodone-Acetaminophen;
New Limited Coverage Drug: Ratio-Zopiclone
Posted February 3, 2003
Saskatchewan
January 2003 Version of the Formulary
Posted January 23, 2003
Nova Scotia
January 2003 Bulletin
Highlights
Criteria for Benefits with Exception Status: Xeloda, Comtan, Gleevac;
Change in Benefit Status Effective February 1, 2003: Mirapex will no longer require a written request for Seniors
and Community Services programs;
New Full Benefit: BD Latitude Lancets, BD Latitude Test Strips;
New Exception Status: Gleevec, Comtan;
Not Insured: Aerius;
Discontinued Products: Alupen, Apo-Salvent, Berotec, Ceftin, Flovent, Hytakerol, Kemadrin, Levobunolol, Mavik, Modulon, Murocel Oph Sol,
Norplant System, Novo-Salmol, Persantine, pms-Desipramine, Prednisolone, PVF K500, Pyridium, ratio-Beclomethasone, ratio-Cimetidine,
ratio-Diltiazem, ratio-Naproxen, ratio-Prazosin, ratio-Salbutamol, ratio-Tiafen, Scheinpharm Ranitidine, Tobramycin, Trandate,
Ulcidinem, Ventolin, Ames Lancets;
DIN Changes: Procytox 25 and 50 mg tabs;
Maximum Allowable Cost List Updates: please see the list for details.
Posted January 17, 2003
Ontario
Formulary Edition No. 38 - effective January 30, 2003
Please see the formulary for details.
Highlights
New Full Benefit Products: Biaxin 250mg/5mL Susp; Biaxin XL 500mg ER Tab;Glucagon 1mg/Vial;
Kadian 10mg SR Cap; Trizivir Tabs; Apo-Amoxi Clav O/L;Apo-Levobunolol Oph Sol; Apo-Medroxy Tabs;
Apo-Methazolamide 50mg Tabs; Apo-Warfarin 3mg Tab; Clobetasol Propionate Cream, Ointment and Scalp Lot;
Gen-Nitro SL 0.4mg/Metered Dose Spray; Gen-Nizatidine Caps; Gen-Propafenone Tabs; Gen-Warfarin Tabs;
Novo-Levocarbidopa Tabs; PMS-Flavoxate Tabs;PMS-Lovastatin Tabs; PMS-Morphine Sulfate SR Tabs;
PMS-Nefazodone Tabs; PMS-Sertraline Caps; Ratio-Lovastatin Tabs;Rhoxal-Sertraline Caps; Sab-Levobunolol Oph Sol;
Sab-Pentasone Oph/Ot Drops; Vitamin B12 -1000mcg/mL 1mg/mL Inj Sol-10mL.
New Limited Use Products: Advair 125 25/125mcg and 250 25/250mcg; Fosamax 70mg Tab;
Lovenox 100mg/mL Inj Sol; Lovenox Pref Syr; Symbicort Turbuhaler; Xatral 10mg Prolong-Rel Tab;
Zyvoxam 600mg Tab;Apo-Clobazam Tabs;Apo-Flunarizine; Apo-Lamotrigine Tabs; PMS-Fluconazole Tabs;
Ratio-IPRA SAL UDV; Rhoxal-Cyclosporine 100mg Cap;
Discontinued Products: Anturan Tabs; Asendin 100mg Tab; Choledyl SA 600mg LA Tab; Cortone 25mg Tab;
Decadron 4mg/mL Inj Sol; Feldene 20mg Cap; Fibyrax Tab; Flagystatin Vag Tab-App; Inflamase Mild 0.125% Oph Sol;
Intal 1% Inh Sol-2mL Pk; Isordil 10mg Tab; Locacorten 0.03% Cr; Loxapac Tabs;
Ludiomil 25mg Tab; Miocarpine 4% Oph Sol; Neptazane 50mg Tab; Neuleptil 10mg Cap; Norventyl 10mg Cap;
Norventyl 25mg Cap; Novo-Gesic C-15 15mg Tab; Novo-Gesic C-30 30mg Tab; Propyl-Thyracil 50mg Tab; Propyl-Thyracil 100mg Tab;
Rimactane 150mg Cap; Rimactane 300mg Cap; Serax 15mg Tab; Teveten 300mg Tab; Urecholine 25mg Tab;
Verelan 180mg SR Cap; Verelan 240mg SR Cap.
Delisted Drugs:
Amitriptyline 10mg Tab; Ampicin Inj Pd-Vial Pk; Ancef 1000mg Inj Pd-Vial Pk;
Antabuse 500mg Tab; Bricanyl Tabs; Cardioquin 275mg Tab; Coronex SL Tabs;
Diazepam 10mg Tab; Dienestrol 0.1mg/g Vag Cr; Dienestrol 0.1mg/g Vag Cr-App;
Erythrocin O/L; Folic Acid 5mg Tab; Humulin Inj (see formulary for details or run a search in iMAM for delisted strengths)
Leritine 25mg Tab; Norinyl Tabs; Novo-Levamisole 50mg Tab; Novo-Rythro Encap 250mg Ent Pel Cap;
One-Alpha 0.2mcg/mL Oral Sol; Ortho Tab-28 Pk; Ortho-Novum Tab-28 Pk; Perphenazine 8mg Tab;
Pylorid 400mg Tab; Retrovir 300mg Tab; Sulamyd 10% Oph Oint-3.5g Pk;
Synalar Bi-Otic Ot Sol; Theo-Dur 450mg LA Tab; Tolectin 200mg Tab;
Tonocard 400mg Tab; Vancenase 50mcg Nas Sp-200.
Not a Benefit:
Erythromid 250mg Tab; Floxin 200mg Tab; Haldol-LA 50mg/mL Oily Inj Sol-5mL Pk; Phenobarbital 15mg Tab; Phenobarbital 30mg Tab;
Phenobarbital 60mg Tab; Serax 10mg Tab; Stelazine 1mg Tab; Stelazine 2mg Tab; Stelazine Tabs;
Tofranil 10mg Tab.
Change in Interchangeability Grouping(s) and New Status: 1)Zoloft and Apo-Sertraline are interchangeable for all
indications; 2) Novo-Sertraline, Gen-Sertraline, PMS-Sertraline, Rhoxal-Sertraline and Apo-Sertraline are interchangeable
with Zoloft for the treatment of depression.
Posted January 16, 2003
NIHB
Drug Bulletin January 2004
Highlights
Additions: Lumigan 0.03% Opth Sol, NovoRapid 100u/ml Inj, Coversyl Plus 4mg/1.25mg Tab,
Crestor 10mg, 20mg, 40mg Tab, Mavik 1mg, 2mg Cap;
New Limited Use Benefits: Pegetron Inj, Spiriva 18mcg Inh, Bextra 10mg Tab, Rapamune 1mg Tab;
Not Listed: Minirin 0.1mg, 0.2mg Tab, Pennsaid 1.5% Sol, Xalacom Opth Sol, Elidel 1% Top Crm,
Avandamet Tabs, Tarka Tabs, Bextra Tabs;
Delisted: Effective November 27, 2003 products containing Nefazodone;
Quantity and Frequency Limits for Blood Glucose Test Strips effective February 1, 2004 to 5 test strips per day in a 100-day period.
When the maximum is exceed a prior approval is required.
Posted January 16, 2003
New Brunswick
Interchangeable Product Additions
Highlights
Claims for products that are reimbursed at Actual Acquisition Cost up to February 9, 2003 will bde subject to a Maximum Allowable Price effective February 10, 2003.
New Interchangeable Product: Simvastatin
Posted January 6, 2003
Saskatchewan
Update Bulletin January 2003
Highlights
New Exception Drug Status: Aranesp, Lovenox 150mg/ml;
New Full Benefits: Lumigan, Apo-Methazolamide, Apo-Amoxi Clav,
Apo-Flunarizine, ratio-IPRA SAL UDV, Gen-Combo Sterinebs;
Exception Drug Status Criteria Modifications: Effective November 20, 2002:
Fosamax, Effective January 1, 2003:
Celebrex, Plavix, Flexeril, Apo-Cyclobenzaprine, Novo-Cycloprine, Nu-Cyclobenzaprine, pms-Cyclobenzaprine, Gen-Cyclobenzaprine,
Med-Cyclobenzaprine, Flexitec, Dom-Cyclobenzaprine, Alertec, Pevacid, Losec, Pantoloc, Pariet;
Delisted Products: Effective April 1, 2003: Cefaclor, Detrol;
Interchangeability Changes: please see the bulletin for details;
Under Review: Arixtra, BD Latitude, Xalacom, Florazole, Pegetron, Zelnorm, Thyrogen, Valcyte;
Discontinued Product: Apo-Zidovudine;
Not Recommended: Kineret, Diamicron, Amaryl, DexIron, Quinine-Odan, Androderm
Posted January 6, 2003
Newfoundland
New Interchange Drug Formulary List effective January 3, 2003
Posted January 3, 2003
NIHB
Winter 2002-2003 Updates
Highlights
Status Change: Plavix now an Open Benefit, Flomax SR now a Limited Use Benefit;
Updates to Limited Use Benefits: Effective May 1, 2002: Gleevec;
Effective August 1, 2002: Botox, Protopic, Symbicort, Xatral;
Effective December 1, 2002: Pariet, Unitdet;
New Limited Use Benefits and Critiera List : Please see the update;
Replacement DINS: Lyteprep, Sofracort, Talwin, Zincofax. For detailed listing of discontinued
drugs and new benefits please see the update.
|
